Tiziana Life Sciences presents at Jefferies
Analysis based on 6 articles · First reported May 28, 2026 · Last updated May 28, 2026
The presentation by Tiziana Life Sciences at the Jefferies Global Healthcare Conference could positively impact the stock price of Tiziana Life Sciences as it provides updates on its clinical programs and strategic direction to institutional investors. Increased investor confidence in Foralumab's development could lead to a rise in the company's valuation.
Tiziana Life Sciences, a biotechnology company, announced that its CEO, Ivor Elrifi, and COO/CFO, Kiran Shah, will deliver a corporate presentation at the Jefferies Global Healthcare Conference in United States — New York City on June 4, 2026. The presentation will highlight recent clinical and corporate updates, particularly concerning its lead candidate, intranasal Foralumab, a fully human anti-CD3 monoclonal antibody. Foralumab is currently in clinical development for Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS), with promising results from an Expanded Access Program and an ongoing Phase 2a trial. The company aims to share its progress and strategic direction with the investment community.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard